Characteristics and management of erectile dysfunction after various treatments for prostate cancer.
Soh
Jintetsu
J
Kaiho
Yasuhiro
Y
Kikuchi
Eiji
E
Oya
Mototsugu
M
Yoshioka
Kunihiko
K
Nakagami
Yoshihiro
Y
Hatano
Tadashi
T
Ozu
Choichirou
C
Horiguchi
Yutaka
Y
Namiki
Kazunori
K
Tachibana
Masaaki
M
Hisasue
Shin-Ichi
S
Tanaka
Nobumichi
N
Asakawa
Isao
I
D000726:Androgen Antagonists / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001918:Brachytherapy / Q000009:adverse effects*; D007172:Erectile Dysfunction / Q000209:etiology* / Q000534:rehabilitation*; D006801:Humans; D010535:Laparoscopy / Q000009:adverse effects; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011468:Prostatectomy / Q000009:adverse effects* / Q000379:methods; D011471:Prostatic Neoplasms / Q000628:therapy*; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects*; D012371:Robotics
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D010726:Phosphodiesterase Inhibitors